Gilead Sciences management check

GILD · Health Care · Biotechnology · CEO Daniel Patrick O'Day

Filings as of

83
Management score, ranked 38th of 487 · 3rd of 60 in Health Care6 good · 1 to watch · 0 flaggedStrongest: owner returns · Weakest: dilution · Best and worst run in Health Care →

The seven checks

  • Good

    Have owners done well?

    Beat its chosen peersOwners$255Peers$125

    What $100 became since fiscal 2021

    100100th
    Detail

    $100 invested at the start of fiscal 2021 grew to $255, against $125 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns20212025

    Pay actually paid $100 value, each on its own scale

    8554th
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.69 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Good

    What does the CEO cost owners?

    0.3% of net income

    $28.4m pay · $8.5bn net income, FY2025

    0.1%1%3%10%
    9087th
    Detail

    $28.4m of reported pay in fiscal 2025, against $8.5bn of net income.

  • Watch

    Do they own the stock?

    CEO stake ≈ 4.0 years of pay

    654,302 shares ≈ $114.6m

    0.1y1y5y20y100y

    6 mo: ▲ $0 bought · ▼ $53.9m sold

    6569th
    Detail

    The CEO holds 654,302 shares, directly or through trusts (unvested awards not counted): about 4.0 years of pay. Light activity: no buys, $53.9m sold in six months. 54 of 54 sales ran on pre-arranged 10b5-1 plans.

  • Good

    Are owners being diluted?

    Share count shrinking2021 · 1.3bn2025 · 1.3bn

    Diluted shares −0.1% a year; flagged above +2%

    0%10%20%

    Stock pay 3.0% of revenue

    5138th
    Detail

    Diluted shares changed -0.1% a year over the last three fiscal years. Stock-based pay was 3.0% of revenue in the latest year.

  • Good

    Is leadership stable?

    7 leadership filings in 3 years

    7 filings under 8-K 5.02 in 3 years

    0101420+

    CEO: Mr. O’Day

    9069th
    Detail

    CEO in the pay table: Mr. O’Day. 7 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 010-K amended
    100100th
    Detail

    No restatements, auditor changes or late filings since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed March 20, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
$0$31.6m$63.3m$10020212022202320242025$255$125

Pay tied most to Net Product Sales

Other key measuresRelative TSRAdjusted Operating Income

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Mr. O’Day$28.4m$63.3m$9.2m$255$125$8.5bn
2024Mr. O’Day$23.7m$44.8m$7.7m$187$93$480.0m
2023Mr. O’Day$22.6m$15.5m$7.6m$157$94$5.6bn
2022Mr. O’Day$21.6m$55.0m$7.9m$161$90$4.6bn
2021Mr. O’Day$19.2m$31.5m$6.3m$130$100$6.2bn

Insiders and the CEO's stakeQuiet

Chairman & CEO
Daniel Patrick O'Day
Shares held
654,302
At that filing's price
≈ $114.6m
Latest Form 4
Nov 5, 2026

Light activity: no buys, $53.9m sold in six months. 54 of 54 sales ran on pre-arranged 10b5-1 plans.

Open-market trades by officers and directors since May 21, 2026.

  • SoldDaniel Patrick O'DayChairman & CEO · 10b5-1 plan$35.3mNov 5, 2026
  • SoldJohanna MercierChief Comm & Corp Aff Officer · 10b5-1 plan$10.3mNov 16, 2026
  • SoldAnthony WeltersDirector · 10b5-1 plan$2.7mAug 26, 2026
  • SoldAndrew D DickinsonChief Financial Officer · 10b5-1 plan$2.6mNov 16, 2026

Leadership and governance on file

20222023202420252026Leadership 11Votes 5
All 11 filings

Latest shareholder vote results: May 4, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $25.1bn returned to owners in buybacks and dividends, 98% of net income, and $3.8bn of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$4.3bn$8.5bn20212022202320242025Shares1.26bn1.26bn1.26bn1.25bn1.25bn
Show the figures
Fiscal year20212022202320242025
Revenue$27.3bn$27.3bn$27.1bn$28.8bn$29.4bn
Net income$6.2bn$4.6bn$5.7bn$480.0m$8.5bn
Stock-based pay$635.0m$637.0m$766.0m$835.0m$894.0m
Buybacks$546.0m$1.4bn$1.0bn$1.1bn$1.9bn
Dividends$3.6bn$3.7bn$3.8bn$3.9bn$4.0bn
Diluted shares1262m1262m1258m1255m1255m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.